Production (Stage)
United Therapeutics Corporation
UTHR
$307.65
-$1.07-0.35%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 5.09% | 38.78% | 15.51% | 7.29% | 27.27% |
| Total Depreciation and Amortization | 32.00% | 43.80% | 43.61% | 44.96% | 12.78% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 172.85% | 110.34% | 86.53% | 227.41% | 328.79% |
| Change in Net Operating Assets | 95.98% | 95.42% | -71.74% | 39.32% | -68.71% |
| Cash from Operations | 22.50% | 126.41% | 8.95% | 118.44% | 0.45% |
| Capital Expenditure | -96.07% | -10.17% | -16.44% | -0.89% | 7.51% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -111.61% | -117.38% | 84.50% | 80.88% | 530.20% |
| Cash from Investing | -122.40% | -392.64% | 63.34% | 64.79% | 432.56% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | 0.00% | -- | -- | -- |
| Issuance of Common Stock | -53.36% | 250.68% | 365.38% | 110.93% | -28.86% |
| Repurchase of Common Stock | 98.49% | -200.00% | -100.00% | -- | -7,391.85% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 0.00% |
| Cash from Financing | 91.22% | 19.50% | -943.42% | -294.33% | -2,297.53% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 362.79% | 43.30% | 390.59% | 208.32% | -78.35% |